olaparib targets prostate cancer mutations Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer. Phosphate-binder therapy does not reduce mortality ...

Newark, NJ, May 30, 2022 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, The global feed binder market is expected to grow from USD 5.10 billion in 2019 to USD 6.58 billion by 2027, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Vifor Pharma's Phase III study on its ...

The medication may represent a new treatment option for dialysis patients, researchers concluded. A team led by Rong Wang, MD, of Shandong Provincial Hospital in Shandong, China, analyzed 8 randomized ...

FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with ...